Oral ganciclovir cost saving in CMV retinitis - German study data

Abstract

T he value of information on the possible economic impact of a new drug or formulation before it is launched is well recognised. Researchers at the University of Hannover, Germany, have conducted a comparative study of the cost and quality-of-life effects of IV and oral ganciclovir in the treatment of cytomegalovirus (CMV) retinitis. Dr Susanne Wähling presented their findings at the International Health Economics Association Inaugural Conference [ Vancouver, Canada; May 1996 ].